FDA in the Twenty-First Century : The Challenges of Regulating Drugs and New Technologies

I. Glenn Cohen

ISBN 10: 0231171188 / ISBN 13: 9780231171182

Editore: Columbia University Press Sep 2015, 2015

Riguardo questo articolo

Neuware - Addresses perennial and new problems and the improvements the FDA can make to better serve the public good.

Codice articolo 9780231171182

Dati bibliografici

• Titolo: FDA in the Twenty-First Century : The Challenges of Regulating Drugs and New Technologies
• Editore: Columbia University Press Sep 2015
• Data di pubblicazione: 2015
• Lingua: Inglese
• ISBN 10: 0231171188
• ISBN 13: 9780231171182
• Rilegatura: Buch
• Condizione: Neu
• Dimensioni: 237 L x 168 A x 41 P (millimetri) 237 millimetri di larghezza per 168 millimetri di altezza per 41 millimetri di profondità
• Peso: 970 grammi

Descrizione articolo

Riassunto

In its decades-long effort to assure the safety, efficacy, and security of medicines and other products, the Food and Drug Administration has struggled with issues of funding, proper associations with industry, and the balance between consumer choice and consumer protection. Today, these challenges are compounded by the pressures of globalization, the introduction of novel technologies, and fast-evolving threats to public health. With essays by leading scholars and government and private-industry experts, FDA in the Twenty-First Century addresses perennial and new problems and the improvements the agency can make to better serve the public good.

The collection features essays on effective regulation in an era of globalization, consumer empowerment, and comparative effectiveness, as well as questions of data transparency, conflicts of interest, industry responsibility, and innovation policy, all with an emphasis on pharmaceuticals. The book also intervenes in the debate over off-label drug marketing and the proper role of the FDA before and after a drug goes on the market. Dealing honestly and thoroughly with the FDA's successes and failures, these essays rethink the structure, function, and future of the agency and the effect policy innovations may have on regulatory institutions abroad.

Informazioni sull?autore

Holly Fernandez Lynch is the executive director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. She is a lawyer and bioethicist, with expertise in the ethics and regulation of human-subjects research and drug development. She is also the author of Conflicts of Conscience in Health Care: An Institutional Compromise.

I. Glenn Cohen is a professor at Harvard Law School and faculty director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. He is the author of more than eighty articles and book chapters and the author, editor, or coeditor of seven books. In addition to the ethics and regulation of drug development, he works on reproductive technologies, medical tourism, rationing, the bioethics of professional sports, and other topics.